A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Titre officiel

LIBRETTO-431: A Multicentre, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Sommaire:

Cette étude a pour but de vérifier si le médicament à l’étude, le selpercatinib, comparativement à un traitement standard, est efficace et sûr chez les participants atteints d’un cancer du poumon non à petites cellules (CPNPC) non squameux positif pour la fusion RET (réarrangement pendant la transfection) s’étant propagé à d’autres parties du corps. Les participants qui se voient attribuer le traitement standard et qui l’interrompent à la suite d’une progression de la maladie ont la possibilité de passer au selpercatinib.

Description de l'essai

Primary Outcome:

  • Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)
  • PFS by BICR (with or without Pembrolizumab)
Secondary Outcome:
  • Disease Control Rate (DCR) by BICR (with Pembrolizumab)
  • DCR by BICR (with or without Pembrolizumab)
  • PFS2 (with Pembrolizumab)
  • PFS2 (with or without Pembrolizumab)
  • Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by BICR (with Pembrolizumab)
  • ORR: Percentage of Participants with CR or PR by BICR (with or without Pembrolizumab)
  • Duration of Response (DoR) by BICR (with Pembrolizumab)
  • DOR by BICR (with or without Pembrolizumab)
  • Overall Survival (OS) (with Pembrolizumab)
  • OS (with or without Pembrolizumab)
  • Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST (Response Evaluation Criteria in Solid Tumours) 1.1 by BICR (with Pembrolizumab)
  • Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with or without Pembrolizumab)
  • Intracranial DOR per RECIST 1.1 by BICR (with Pembrolizumab)
  • Intracranial DOR per RECIST 1.1 by BICR (with or without Pembrolizumab)
  • Time to Deterioration of Pulmonary Symptoms (with Pembrolizumab)
  • Time to Deterioration of Pulmonary Symptoms (with or without Pembrolizumab)
  • The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)
  • Time to CNS Progression per RECIST 1.1 by BICR (with Pembrolizumab)
  • Time to CNS Progression per RECIST 1.1 by BICR (with or without Pembrolizumab)
  • Intracranial ORR: Percentage of Participants with Intracranial CR or PR per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) by BICR (with Pembrolizumab)
  • Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with or without Pembrolizumab)
  • Intracranial DOR per RANO-BM by BICR (with Pembrolizumab)
  • Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer